Table 4 Criteria weights
Criterion | SMART Ranking | Swing weighting (see Table 3) | Relative scores for swing weighting | Weight of non-price criteria | Draft Weights | Final weights of initial MCDA |
|---|---|---|---|---|---|---|
Price advantage | N/A | 50.0% | 40.0% | |||
Quality assurance | 1 | Vote 5: + 50% | 51.75 | 31.4% | 15.7% | 18.8% |
Equivalence with the reference (original) product | 2 | Vote 4: + 0% (=equal importance) | 34.5 | 20.8% | 10.4% | 12.5% |
Product stability and drug formulation | 2 | Vote 3: + 50% | 34.5 | 20.8% | 10.4% | 12.5% |
Reliability of drug supply | 3 | Vote 2: + 100% | 23 | 14.0% | 7.0% | 8.4% |
Real world clinical or economic outcomes such as adherence or non-drug costs | 4 | Vote 1: + 15% | 11.5 | 7.0% | 3.5% | 4.2% |
Pharmacovigilance | 5 | N/A | 10 | 6.0% | 3.0% | 3.6% |